It's hard to escape the positive vibe that is currently circulating within the optics industry. As well as publishing record results in quarter one, many of the industry's big hitters have also published encouraging growth forecasts for ...
Tags: optics industry, cosmetic medical systems, semiconductor tools
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN® for use ...
SAN DIEGO,Jan.26(UPI)--A California electrician developed star-shaped cataracts in his eyes after 14,000 volts of electricity passed through his body,his doctor says. Dr.Robert S.Korn of the University of California,San Diego,said the ...
Tags: Eyes, optic nerve, cataract surgery
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK), a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted final approval for the Company's Abbreviated New Drug Application, (ANDA) for Bromfenac ...
A new gene therapy that successfully treated a rare eye disease in clinical trials could prove the key to preventing more common inherited causes of blindness, researchers say. In six male patients, doctors used a virus to repair a ...
The U.S. Food and Drug Administration today approved the first gel sealant for use in stopping fluid from leaking through the incision in a patient's cornea after cataract surgery with intraocular lens placement in adults. Prior to today's ...
Tags: Gel for Sealing Corneal Incision, First Gel After Cataract Surgery
A sealant gel to prevent fluid leakage after cataract surgery has been approved by the U.S. Food and Drug Administration. While gels such as ReSure have been approved to seal small incisions in other parts of the body, this is the first ...
Tags: Sealant Gel, Eye Surgery
The elimination of extensive routine preoperative tests and consultations represents an area of potentially large health care savings across many disciplines, particularly for low-risk patients being evaluated for cataract surgery. It is ...
Avedro (Waltham, MA) landed a CE Mark in the European Union for its non-surgical myopia treatment device. The device, dubbed KXL II, can perform a photorefractive intrastromal cross-linking procedure, allowing for the correction of myopia. ...
Tags: Myopia Treatment Device, CE Mark
The US Food and Drug Administration’s (FDA) Ophthalmic Devices Panel announced that Ocular Therapeutix’s ReSure sealant is safe and effective in managing clear corneal wound leaks following cataract surgery. ReSure Sealant is ...
Tags: Ocular Therapeutix, Medicine
The US Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel is scheduled to decide on Ocular Therapeutix’s premarket approval application for the ReSure Sealant in September and may suggest some recommendations. ...
Tags: Ophthalmic Devices, Health
US-based Abbott has agreed to buy a stent maker and an eye surgery systems manufacturer in two separate deals, worth about $710m, as part of its strategy to expand its medical device business. Illinois-based Abbott agreed to purchase ...
Tags: Stent Maker, Ophthalmic Device
Bausch + Lomb and Technolas Perfect Vision have received 510(k) clearance from the US Food and Drug Administration (FDA)for Victus Femtosecond Laser platform, designed for use during cataract and corneal surgical procedures. The CE-marked ...
Tags: FDA, Victus platform, surgical procedures, platform
InSite Vision has launched a new DuraSite 2 drug delivery system, designed to deliver ophthalmic therapeutics. DuraSite 2, which is based on InSite DuraSite technology, incorporates cataract surgery drug, ketorolac, a non-steroidal ...
Tags: InSite, Ophthalmic Drug Delivery System, ophthalmic therapeutics
Ophthalmologic products provider, InSite Vision has started the patient enrollment for the first Phase 3 clinical trial of BromSite (ISV-303), which is used to reduce pain and inflammation post cataract surgery. The study will enroll ...
Tags: Insite Vision, BromSite Phase 3 Study, Ophthalmologic products